Anti-IL-2 Antibodies And Compositions And Uses Thereof

Tech ID: 32019 / UC Case 2014-100-6

Technology Description

UCSF, Pfizer, and Stanford investigators developed a novel anti-IL2 mAb for the treatment of autoimmune and inflammatory diseases, including without limitation, Type I diabetes mellitus, psoriasis, Crohn's disease, adult respiratory distress syndrome, rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis, and autoimmune thyroiditis. Unlike other treatments for autoimmune and inflammatory diseases, this antibody targets the underlying pathogenic pathway rather than merely treating the symptoms. Specifically, when complexed with IL-2, this antibody can selectively expand regulatory T-cells (Tregs) by releasing IL-2 specifically to Tregs.

Existing low dose IL-2 and IL-2 Mutein therapies show clinical promise, but have a narrow therapeutic window. Too high doses can cause cancer, while insufficient doses are ineffective. The specificity of the therapeutic described here would allow for higher doses without carcinogenic side effects. Furthermore, this antibody complex is less complicated to manufacture than Pegylated IL2.

Related Materials

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 10,138,298 11/27/2018 2014-100
Japan Published Application 2018-537962 12/27/2018 2014-100
China Published Application 109071648 12/21/2018 2014-100
European Patent Office Published Application 3365369 08/29/2018 2014-100
Rep Of Korea Published Application 10-2018-0064541 06/14/2018 2014-100
Australia Published Application 2014-100
New Zealand Published Application 2014-100

Additional Patents Pending


Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information


autoimmune, inflammatory disease, type I diabetes, lupus

Categorized As